You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Bloomberg reports that vaccine developers won't have to conduct large trials of updated vaccines or vaccine boosters aimed at new viral variants.
The SARS-CoV-2 variant uncovered in California may be more transmissible and partially evade vaccine-induced antibody response, the Los Angeles Times reports.
Francis deSouza, the CEO of Illumina, calls for a global SARS-CoV-2 genomics surveillance network, according to the Financial Times.
In PNAS this week: immunotherapy for hard-to-treat breast cancers, effects of oncogenic histone H3K36M mutations, and more.
The New York Times writes that the unfilled top spot at the US Food and Drug Administration is "glaring."
The Canadian COVID-19 Genomics Network aims to increase its genomic surveillance of emerging SARS-CoV-2 strains, the Canadian Press reports.
Reuters reports that no serious safety concerns have been identified in the first month of SARS-CoV-2 vaccinations in the US.
In PLOS this week: actionable pharmacogenetic variants in Hong Kong population, role of defective viral genomes, and more.
Researchers have cloned the endangered black-footed ferret, the New York Times reports.
According to BBC News, the UK is to launch its new "high-risk" science agency.
DNA testing ties one coyote linked to three previous attacks to a new biting incident in the Bay Area, the San Francisco Chronicle reports.
In Science this week: cell-free DNA from urine explored to help diagnoses, more.
Two studies indicated that the SARS-CoV-2 vaccines from Pfizer-BioNTech and Moderna have lower neutralizing antibody responses to the B.1.351 viral lineage, according to the Washington Post.
The Chronicle of Higher Education reports that the number of international graduate students in the US has fallen during the COVID-19 pandemic.
According to Politico, President Joe Biden is to nominate Chiquita Brooks-LaSure to lead the Centers for Medicare and Medicaid Services.
In Nature this week: analysis of SARS-CoV-2 genomes uncovered substrains in the US.
The AP reports that a bill introduced to the US House of Representatives would provide $1.75 billion to sequence SARS-CoV-2 samples to spot viral changes.
The UK has given the go-ahead to a SARS-CoV-2 human challenge trial, Reuters reports.
CNN reports that a new study has found SNP chips do not reliably identify rare variants.
In Nucleic Acids Research this week: targeted splice sequencing study of myotonic dystrophy, structural variant genotyping tool, and more.
The New York Times writes that researchers have uncovered more than a half dozen SARS-CoV-2 lineages with a Q677P alteration.
The Wall Street Journal reports that a sizable portion of the 150 million rapid antigen tests the US bought have gone unused.
According to Stat News, Bluebird Bio has suspended its sickle cell gene therapy clinical trials after a patient developed leukemia.
In PNAS this week: single-cell whole-genome amplification approach for SNV detection, immune features linked to bone regeneration, and more.
KTLA reports that a SARS-CoV-2 variant first identified in California is present across the US and abroad.
According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.
NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.
In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.
Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.